Rossella Elisei

Rossella Elisei is an Italian endocrinologist and leading expert in medullary thyroid cancer, particularly the genetic epidemiology of RET proto-oncogene mutations and their correlation with clinical outcomes. She contributed to defining the relationship between specific RET codon mutations and MTC aggressiveness, enabling genotype-phenotype correlations used in ATA risk stratification guidelines. Elisei was a principal investigator in the ZETA trial establishing vandetanib as the first approved systemic therapy for progressive MTC and has participated in development of RET-selective inhibitor trials. Her research on calcitonin doubling time as a prognostic biomarker has influenced monitoring guidelines.